Opko Health (OPK) Owns Piece of VBI Vaccines (VBIV); Advanced Micro Devices (AMD) Surges on Analyst’s Viewpoint


Multinational pharmaceutical and diagnostics company Opko Health Inc. (Nasdaq:OPK) disclosed after the closing-bell Friday in a regulatory filing ( SC 13D ) with the Securities and Exchange Commission (SEC) a 15% stake (6,023,014 shares) in VBI Vaccines, Inc. (Nasdaq:VBIV).

Last week, VBI Vaccines released a corporate presentation highlighting opportunities for its pipeline portfolio in the areas of infectious disease (hepatitis B, cytomegalovirus, zika) and immuno-oncology (gioblastoma multiforme, medulloblastoma), and ongoing collaborations for its LPV Platform with Sanofi SA (NYSE:SNY) and GlaxoSmithKline plc (NYSE:GSK).

VBIV stock closed at $5.49, up $0.06 (or +1.10%) with a total volume of 64,150 shares traded on Friday.

VBI Vaccines, a commercial-stage biopharmaceutical company developing vaccine candidates and novel technology platforms, has 40.02M shares outstanding, market capitalization (intraday) of $219.74M and VBIV stock 52-week range is between $2.75 and $6.60 per share.



Shares of Advanced Micro Devices, Inc. (Nasdaq:AMD) climbed 3.56% (or +$0.50) to $14.55 on Friday’s trading session after brokerage firm Macquarie initiated coverage on its stock with a Neutral rating and a price target of $14.00

The semiconductor company said at the end of January that it expects first-quarter fiscal 2017 revenue to decrease sequentially by 8% to 14%.

Advanced Micro Devices, which develops computer processors and related technologies for business and consumer markets, has 941.40M shares outstanding, market capitalization (intraday) of $13.70B and AMD stock one-year range is from $2.60 to $15.55 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/